Market Overview

Bryan Lindsey Signs Agreement to Invest in ChromoCare™

Share:

Bryan Lindsey Signs Agreement to Invest in ChromoCare™

Bryan Lindsey has solidified an agreement to invest an undisclosed amount of funding in ChromoCare™, a leading genetics-testing firm that has developed a proprietary test and multifactorial algorithm related to medication compatibility within 24 genes in the human body.

PR Newswire

COLUMBUS, Ohio, Aug. 29, 2018 /PRNewswire-PRWeb/ -- Bryan Lindsey has solidified an agreement to invest an undisclosed amount of funding in ChromoCare™, a leading genetics-testing firm that has developed a proprietary test and multifactorial algorithm related to medication compatibility within 24 genes in the human body. This investment makes Lindsey the single largest outside investor in ChromoCare™ in North America.

ChromoCare™'s leading product is The G•A•P Test™. The test is able to identify when a patient will not benefit from 350+ medications, including opiates, due to their genetic inability to metabolize the drug. ChromoCare™'s next product, ChromoALERT™, is a platform that enables the patient and physician insight into the individual's genetic based susceptibility to addiction. These two factors can now be utilized to inform treatment decisions and provide safer pain management treatment.

The G•A•P Test™ is a genetic medication-compatibility test that brings added insight, reduces adverse events and the need for repeat office visits or ER visits, due to incompatible drug or dosage issues. Saving lives, saving time and saving money.

ChromoCare™ is proving that patients who use the G•A•P Test™ will save thousands of dollars on both pharmacy and medical-claims costs for their employers.

"I am so excited to partner with ChromoCare™! ChromoCare™ is positioned to create significant category disruption in the $3 Trillion healthcare industry in the U.S. alone. I have invested in several domestic and international companies; however, I am the most excited about this stake in ChromoCare™," states Lindsey.

"The Pharmaceutical industry generates over $1 Trillion dollars globally and costs employees and employers hundreds of billions of dollars per year. We have proven that with ChromoCare™ we will reduce these costs to both employees and employers and solidify our category leading position in this space. We anticipate we will generate significant revenue for ChromoCare™ while simultaneously saving lives, time and billions of dollars for hard-working Americans and business owners," Lindsey continued.

Founded in 2013 by Jeff Garshon, president, the company is led by Chairman & CEO Hugh Cathey, Garshon, and COO Jodie Fortine. Cathey is a proven leader in the healthcare space and others, including telecommunications companies where he has served as the senior executive in both public and private companies.

ChromoCare™ is a growing company quickly in its industry. Their innovation in Precision Medicine and Pharmacognetics (PGx) leverages the latest technology and has been instrumental in driving the company's growth.

Chairman and CEO Hugh Cathey said, "We are very excited that Lindsey has decided to invest with ChromoCare™. He has a proven track record of successful investments globally and we are looking forward to his involvement in assisting us to continue our mission of creating a category changing role in the Pharmacogenetics space."

Cathey explains, "ChromoCare™ has established a leadership position in this space with its customers (large employer groups), unique culture, and relentless focus on patient delivery. We are excited to partner with Lindsey and the existing management team to continue our path of being a leading company in this category. With access to this capital, as well as our many years of experience in this space, we are confident that this investment will significantly accelerate the company's growth trajectory."

The transaction has closed and ChromoCare™ is definitely excited about our enhanced direction and focus.

About ChromoCare™
Founded in Ohio in 2013, ChromoCare™ is in a leading position to positively impact the healthcare outcomes and costs of medical claims in the world of self-insured Employer Groups, who make up 65% of all companies in the United States.

About Bryan Lindsey:
Bryan is a multifaceted investor, business owner, seasoned hospitality leader and philanthropist. One of his most notable partnerships is with Tuff-N-Uff MMA, the largest amateur mixed martial arts organization in the world and developer of the future stars of MMA, such as superstar Ronda Rousey. The senior level executive had spent nearly 20 years with Station Casinos, now named Red Rock Resorts Inc. (RRR) and recently left his position post the RRR initial public offering, which resulted in the company raising $531.4 million. He held numerous positions, both at the property level at resorts such as Green Valley Ranch in Henderson and Red Rock Resort in Summerlin, as well as at the Corporate Headquarters. Bryan is very active in the Las Vegas Valley community. He is a Commissioner for the City of Henderson, Board Member and Vice President of the Board of the United States Congressional Awards of Nevada, Board Member for the Henderson Chamber of Commerce, Board Member & member of the Executive Board for the Boys & Girls Club of Southern Nevada, Former Chairman of the American Heart Association, Top Fundraiser in the State of NV and Top 10 in the Nation for the American Cancer Society REAL MEN WEAR PINK campaign, as well as Board Member of CEOs against Cancer. He and his family enjoy participating in Noah's Animal House fundraising events. Bryan is married and lives with his wife and two daughters in Henderson.

 

SOURCE ChromoCare

View Comments and Join the Discussion!